Product Description
Pegylated Human Recombinant Arginase for Liver Cancer (Sourced from: https://clinicaltrials.gov/ct2/history/NCT00988195?V_2=View)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bio-Cancer Treatment International Limited
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|